Shuangwei Li

This paper describes the development of orally bioavailable SARS-CoV-2 protease inhibitors with a hydroxymethyl ketone warhead, showing improved potency and bioavailability compared to previous compounds.

This paper identifies mCMQ069, a novel antimalarial with potential for single-dose cure and one-month chemoprevention, showing improved pharmacokinetic properties over KAF156.

This paper introduces CMX990, a potent SARS-CoV-2 3CL protease inhibitor with improved potency and clearance compared to nirmatrelvir, advancing to Phase 1 clinical trials.